Immunomodulatory and anti-tumor related nanoantibodies, nucleic acid coding sequences thereof and applications

By developing nano-antibody that can specifically bind HLA-G, PD-L1 and CD3ε to form TriTE and activate T cells, it solves the problem that the existing tumor treatment methods are not effective and effectively treats a variety of cancers.

CN115124625BActive Publication Date: 2024-11-26SHINE ON BIOMEDICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210297132.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-03-24
Filing Date
2022-03-23
Publication Date
2024-11-26
Estimated Expiration
2042-03-23

AI Technical Summary

Technical Problem

The existing tumor treatment methods are not effective and have strong side effects, making it difficult to effectively activate the immune system to attack tumor cells, especially because the target molecules such as HLA-G, PD-L1 and CD3ε inhibit immune function in tumors, resulting in limited therapeutic effects. .

Method used

Develop a nanoantibodynamic to form a trispecific T-cell adapter (TriTE) through specific binding of HLA-G, PD-L1 and CD3ε, activate and aggregate CD3-positive cells, enhance T cell activation and proliferation, and promote Killing tumor cells.

Benefits of technology

This nanoantibodies can specifically bind to target molecules, activate T cells, enhance the killing ability of tumor cells, and directly administered through large-scale in vitro preparation, significantly inhibiting the growth of cancer cells and improving the treatment of lung adenocarcinoma, breast cancer, and nerves The efficacy of glioblastoma, ovarian cancer, etc.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115124625B_ABST
    Figure CN115124625B_ABST
Patent Text Reader

Abstract

The present invention provides an immunomodulatory and anti-tumor-related nanoantibody, which specifically binds to human leukocyte antigen-G, programmed cell death ligand 1 and CD3ε, and the immunomodulatory and anti-tumor-related nanoantibody comprises a combination of the following amino acid sequences: SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3. The present invention also provides a nucleic acid encoding sequence of the immunomodulatory and anti-tumor-related nanoantibody, and the use of the immunomodulatory and anti-tumor-related nanoantibody for treating cancer and immune-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an immunomodulatory and anti-tumor related nano antibody, its nucleic acid coding sequence and its application.

[0002] Prior Art

[0003] Cancer, also known as malignant tumor, is an abnormal proliferation of cells that may invade other parts of the body. It is a disease caused by the abnormal control of cell division and proliferation. The number of people suffering from cancer in the world is increasing. Cancer is one of the top ten causes of death in China and has been ranked first for many years.

[0004] Conventional tumor treatment methods include surgery, radiotherapy, chemotherapy and targeted therapy. Tumor immunotherapy is another method of treating tumors besides the above treatment methods. It activates the patient's own immune system, uses tumor cells or tumor antigens to induce the body's specific cellular immunity and humoral immune response, enhances the body's anti-cancer ability, and prevents tumor growth, spread and recurrence, so as to achieve the purpose of eliminating or controlling tumors. However, current tumor treatment methods still have problems such as ineffectiveness and strong side effects, and may even lead to other immune-related diseases.

[0005] Human leukocyte antigen-G (HLA-G) has been found to be highly expressed in a variety of solid tumors and has the property of suppressing immune cells. Therefore, researchers have been committed to developing HLA-G as a target molecule for tumor identification and finding out whether these target molecules have the potential to become anti-cancer drugs.

[0006] Programmed cell death ligand 1 (PD-L1) has been found to be expressed on the cell surface of various solid tumors. Therefore, researchers have been committed to developing PD-L1 as a target molecule for identifying tumors and finding out whether these target molecules have the potential to become anti-cancer drugs.

[0007] CD3ε (CD3 epsilon) is a transmembrane protein found on T cells, which has been found to be associated with tumors and immune regulation. Therefore, researchers have been committed to developing CD3ε as a target molecule for identifying tumors and regulating immune function and finding out whether these target molecules have the potential to become anti-cancer drugs or immunomodulatory drugs.

[0008] In order to solve the above problems, technicians in this field are in urgent need of developing novel and more effective drugs for treating cancer and immune-related diseases, immunomodulation and activation of immune cells to benefit the vast population in need. Summary of the invention

[0009] In view of this, the purpose of the present invention is to provide an immunomodulatory and anti-tumor related nanoantibody, which specifically binds to human leukocyte antigen-G (human leukocyte antigen-G, HLA-G), programmed cell death ligand 1 (programmed cell death ligand 1, PD-L1) and CD3ε (CD3epsilon), and the immunomodulatory and anti-tumor related nanoantibody comprises a combination of the following amino acid sequences: SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

[0010] In one embodiment of the present invention, the amino acid sequence is the amino acid sequence of the heavy chain variable domain (VHH) of the immunomodulatory and anti-tumor related Nanobody.

[0011] In one embodiment of the present invention, the immunomodulatory and anti-tumor related nanobody further comprises a fragment crystallizable region (Fc region).

[0012] In one embodiment of the present invention, the immunomodulatory and anti-tumor related nanobody is conjugated with a second antibody to form a triple specific T-cell engager (TriTE).

[0013] In one embodiment of the present invention, the immunomodulatory and anti-tumor related nanoantibodies activate and / or aggregate CD3 positive cells.

[0014] In one embodiment of the present invention, the immunomodulatory and anti-tumor related nano-antibodies have the effect of killing tumor cells.

[0015] In one embodiment of the present invention, the tumor cell is selected from the group consisting of lung adenocarcinoma cells, breast cancer cells, glioblastoma cells, ovarian cancer cells, oral cancer cells, and combinations thereof.

[0016] Another object of the present invention is to provide an isolated nucleic acid encoding the amino acid sequence of the immunomodulatory and anti-tumor related nanoantibodies as described above, wherein the isolated nucleic acid comprises a combination of the following nucleotide sequences: SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

[0017] Another object of the present invention is to provide a pharmaceutical composition comprising the immunomodulatory and anti-tumor related nanoantibodies as described above and a pharmaceutically acceptable carrier.

[0018] Another object of the present invention is to provide a use of the immunomodulatory and anti-tumor related nano-antibodies as described above for preparing drugs for treating cancer and immune-related diseases.

[0019] In one embodiment of the present invention, the cancer is selected from the group consisting of lung adenocarcinoma, breast cancer, glioblastoma, ovarian cancer, oral cancer, and combinations thereof.

[0020] In summary, the efficacy of the immunomodulatory and anti-tumor related nanoantibodies of the present invention is that: the surface plasmon resonance binding assay (SPR binding assay) proves that it can specifically bind to HLA-G, PD-L1 and CD3ε, and the T cell (ie, peripheral blood mononuclear cell, PBMC) proliferation and activation assay (T cell (ie, peripheral blood mononuclear cell, PBMC) proliferation and activation assay) proves that it can promote T cell cluster proliferation and activation, enhance the proliferation of CD3-positive T cells in PBMC, and immunocytochemistry (immunocytochemistry, ICC) staining proves that it can bind to tumor cells and kill tumor cells, and enzyme linked immunosorbent assay (enzyme linked immunosorbent assay, ELISA) proves that it can enhance the secretion of cytokines in tumor cells. It has been proved that it can inhibit the growth of cancer cells through animal experiments, thereby achieving the effect of treating cancer and immune-related diseases. In particular, compared to conventional antibodies that must be transfected into cells via vectors to express antibody function, which has the disadvantages of low yield and unclear effect, the immunomodulatory and anti-tumor related nanobodies of the present invention can be directly administered to individuals in need for treatment after large-scale preparation in vitro.

[0021] The following will further illustrate the implementation mode of the present invention. The following examples are used to illustrate the present invention, not to limit the scope of the present invention. Anyone skilled in the art may make some changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention shall be determined by the definition of the attached claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1AThe structure and composition of an immunomodulation and anti-tumor-related nanobody (i.e., a PD-L1 x HLA-G x CD3ε nanobody-based triple specific T-cell engager, PD-L1 xHLA-G x CD3ε nanobody-based TriTE, hereinafter referred to as Nb-TriTE) are shown, wherein anti-HLA-G represents an anti-human leukocyte antigen-G (HLA-G) nanobody, whose amino acid sequence is SEQ ID NO: 1, and the nucleotide sequence encoding the amino acid sequence of the anti-HLA-G nanobody is SEQ ID NO: 4; anti-PDL1 represents an anti-programmed cell death ligand 1 (PD-L1) nanobody, whose amino acid sequence is SEQ ID NO: 2, and the nucleotide sequence encoding the amino acid sequence of the anti-PD-L1 nanobody is SEQ ID NO: 5; anti-CD3e represents an anti-CD3ε nanobody, whose amino acid sequence is SEQ ID NO: 3. NO: 3, the nucleotide sequence encoding the amino acid sequence of the anti-CD3ε nanobody is SEQ ID NO: 6; the signal peptide (Signalpeptide), whose amino acid sequence is SEQ ID NO: 7, and the nucleotide sequence encoding the amino acid sequence of the signal peptide is SEQ ID NO: 8; VHH1 represents the heavy chain variable domain 1 (VHH1), which is the anti-PD-L1 nanobody; the flexible linker (Flexiblelinker), which is the linker (Linker), whose amino acid sequence is SEQ ID NO: 9, and the nucleotide sequence encoding the amino acid sequence of the flexible linker is SEQ ID NO: 10; VHH2 represents the heavy chain variable domain 2 (VHH2), which is the anti-HLA-G nanobody; VHH3 represents the heavy chain variable domain 3 (VHH3), which is the anti-CD3ε nanobody; Hinge (Hinge); CH2 and CH3 represent the human IgG1 crystallizable fragment region (fragment crystallizable region, Fc region), which is the human IgG1 Fc-domain (HumanIgG1 The amino acid sequence of the Fc-domain of human IgG1 is SEQ ID NO: 11, and the nucleotide sequence encoding the amino acid sequence of the Fc-domain of human IgG1 is SEQ ID NO: 12.

[0023] Figure 1BThe restriction enzyme digestion results of Nb-TriTE are shown, wherein lane 1 represents plasmid, lane 2 represents plasmid digested with XbaI-BamHI, and lane M represents DNA molecular weight standard (DNA marker).

[0024] Figure 1C Shown are the results of gel electrophoresis analysis of purified Nb-TriTE.

[0025] Figure 2A SPR kinetic analysis showing the binding of Nb-TriTE to PD-L1, with ligand being PD-L1, analytical concentrations being 100, 50, 25, 12.5, 6.25, 3.125, 1.5625, and 0.78125 nM, a flow rate of 30 μL / min, an association time of 120 seconds, and a dissociation time of 900 seconds. Atezolizumab is an IgG1 isotype fully humanized anti-PD-L1 monoclonal antibody used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer, small cell lung cancer, and hepatocellular carcinoma. Anti-PDL1 indicates anti-PD-L1 nanobody, Response indicates response, and Time indicates time.

[0026] Figure 2B Figure 3 SPR kinetic analysis showing the binding of Nb-TriTE to HLA-G, the ligand is HLA-G, the analysis concentrations are 305, 152.5, 76.25, 38.125, 19.0625 nM, the flow rate is 30 μL / min, the association time is 180 sec, the dissociation time is 360 sec, anti-HLA-G indicates anti-HLA-G nanobody, anti-CD3e indicates anti-CD3ε nanobody, 87G indicates commercial anti-HLA-G monoclonal antibody, Response indicates response, and Time indicates time.

[0027] Figure 2C SPR kinetic analysis showing the binding of Nb-TriTE to CD3ε, the ligand is CD3ε, the analysis concentrations are 28.125, 56.25, 112.5, 225, 450, 900, 1800, 3600 nM, the flow rate is 15 μL / min, the association time is 350 sec, the dissociation time is 900 sec, anti-CD3e represents anti-CD3ε nanoantibody, Muromonab-CD3 is an immunosuppressant for reducing acute rejection reactions in patients receiving organ transplants, and is a monoclonal antibody against the CD3 receptor on the surface of T cells, response (Response), time (Time).

[0028] Figure 3 The results of T cell proliferation analysis using Nb-TriTE are shown, where PBMC represents peripheral blood mononuclear cell.

[0029] Figure 4 It shows that for tumor cells, T cells and Nb-TriTE (i.e. V H The immunocytochemistry (ICC) staining results of H nanoantibodies. The cell line A549 used is a human non-small cell lung cancer cell line. PBMC represents peripheral blood mononuclear cells. VHH represents Nb-TriTE. The number of cells in the above figure is 1x10 5 The number of cells in the figure below is 4x10 4 Pieces / hole.

[0030] Figure 5A The results of Nb-TriTE and PBMC in enhancing the cytolysis of human cancer cell lines are shown, wherein A549 represents human lung adenocarcinoma cell line, 231 represents MDA-MB-231-human breast cancer cell line, U87 represents glioblastoma cell line, SKOV3 represents human ovarian cancer cell line, FaDu represents human oral cancer cell line, the ratio of PBMC to A549 cells is 3:1, the concentration of Nb-TriTE is 10μg / ml, and the co-culture lasts for 48 hours.

[0031] Figure 5B The results of Nb-TriTE and PBMC in enhancing the cell lysis of human lung adenocarcinoma cell line A549 are shown, where the concentrations of Nb-TriTE are 0, 1, 10, 100, 1000, 10000 and 100000 μg / ml, the effector (E) cells are PBMCs, the target (T) cells are A549 cells, and the E:T ratio represents the effector / target ratio.

[0032] Figure 6The results show that Nb-TriTE enhances the cytokine secretion of A549 and PBMC co-cultured, where A549 represents human lung adenocarcinoma cell line, Nb represents nanoantibody, effector (E) cells are PBMC, target (T) cells are A549 cells, E:T ratio represents effector / target ratio, # represents not detected, perforin, granzyme B, TNF-α represents tumor necrosis factor alpha, IFN-γ represents interferon gamma, and co-culture lasts for 48 hours.

[0033] 7A to 7C Nb-TriTE was shown to block lung cancer growth in humanized mice. Fig. 7A Luc indicates luciferase, PBMC indicates peripheral blood mononuclear cells, A549 indicates human lung adenocarcinoma cell line, and TriTE indicates Nb-TriTE. DETAILED DESCRIPTION

[0034] definition

[0035] The numerical values ​​used in this article are approximate values, and all experimental data are expressed in the range of ±20%, preferably in the range of ±10%, and most preferably in the range of ±5%.

[0036] As used herein, the terms "immunomodulatory and anti-tumor related nanobodies" and "trispecific T-cell engagers based on PD-L1, HLA-G and CD3ε nanobodies", "Nb-TriTE" and "V H "H nanobody" can be used interchangeably.

[0037] As used herein, the terms "CD3e", "CD3epsilon" and "CD3epsilon (epsilon)" are used interchangeably.

[0038] As used herein, the term "second antibody" means an antibody that can be conjugated to a nanobody to form a trispecific T-cell engager (TriTE). Preferably, the second antibody may include, but is not limited to: anti-CD3ε, CD3, human leukocyte antigen-G (HLA-G), programmed cell death ligand 2 (PD-L2), T-cell immunoglobulin domain and mucin domain 3 (Tim3), epidermal growth factor receptor (EGFR), EGFRvIII, human epidermal growth factor receptor 2 (Her2), B cell maturation antigen (BCMA), CD19, CD20, CD34, CD16, Fc, epithelial cell adhesion molecule (EpCAM), mesothelin, New York esophageal squamous cell carcinoma-1 (NY-ESO-1), glycoprotein 100 (gp100) and mucin 1 (Muc1) antibodies.

[0039] As used herein, "treating" or "treatment" means alleviating, reducing, ameliorating, relieving or controlling one or more clinical signs of a disease or disorder, as well as lowering, stopping or reversing the progression of the severity of the condition or symptom being treated.

[0040] The drug according to the present invention can be manufactured into dosage forms suitable for parenteral administration using techniques well known to those skilled in the art, including, but not limited to, injections [e.g., sterile aqueous solutions or dispersions], sterile powders, tablets, troches, lozenges, pills, capsules, dispersible powders or granules, solutions, suspensions, emulsions, syrups, elixirs, slurries and the like.

[0041] The medicament according to the present invention can be administered by parenteral routes selected from the group consisting of: intraperitoneal injection, subcutaneous injection, intraepidermal injection, intradermal injection, intramuscular injection, intravenous injection and intralesional injection.

[0042] The drug according to the present invention may contain a pharmaceutically acceptable carrier widely used in drug manufacturing technology. For example, the pharmaceutically acceptable carrier may contain one or more agents selected from the group consisting of: solvent, emulsifier, suspending agent, decomposer, binder, excipient, stabilizer, chelating agent, diluent, gelling agent, preservative, lubricant, absorption delaying agent, liposome and the like. The selection and amount of these agents fall within the professional qualities and routine technical scope of those skilled in the art.

[0043] The pharmaceutically acceptable carrier according to the present invention comprises a solvent selected from the group consisting of: water, normal saline, phosphate buffered saline (PBS), a sugar solution, an aqueous solution containing alcohol, and a combination thereof.

[0044] As used herein, the terms "nucleic acid", "nucleic acid sequence" or "nucleic acid fragment" refer to a deoxyribonucleotide sequence or a ribonucleotide sequence in single-stranded or double-stranded form, and contain known naturally occurring nucleotides or artificial chemical mimics. As used herein, the term "nucleic acid" is used interchangeably with "gene", "cDNA", "mRNA", "oligonucleotide" and "polynucleotide".

[0045] Example 1. Preparation of immunomodulatory and anti-tumor related nanobodies

[0046] In this embodiment, the preparation process of immunomodulatory and anti-tumor related nanobodies (i.e., a trispecific T-cell engager based on PD-L1, HLA-G and CD3ε nanobody (PD-L1 x HLA-G x CD3ε nanobody-based triplespecific T-cell engager, PD-L1 x HLA-G x CD3ε nanobody-based TriTE), hereinafter referred to as Nb-TriTE) is as follows. The Nb-TriTE gene is constructed in the expression vector pcDNA3.4 (ampicillin (Amp) resistance). The plasmid was identified by restriction enzyme digestion and sequencing verification. The plasmid was transduced into 293F cells by fluorescent gold nanocluster 3000 (lipofectamine3000) and acted at 37°C and 8% CO2 for 3 days. The supernatant was obtained by centrifugation. The supernatant was combined with protein A beads (1 mL) by flow-through. The protein A beads were washed and eluted with a buffer containing an appropriate gradient of imidazole (10mM, 20mM, 50mM, 100mM, 250mM and 500mM). The eluted fraction was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the subsequent purification scheme (ion exchange chromatography or gel filtration chromatography) was determined based on the purity and yield of the protein. The protein that met the requirements was separated and purified by gel filtration chromatography, and the buffer was changed to phosphate buffered saline (PBS) buffer. The protein components were analyzed by SDS-PAGE, and the components that met the requirements were combined and concentrated, filtered with a 0.22μm filter membrane and packaged. The protein was stored at -20°C or lower.

[0047] The structure and composition of Nb-TriTE are shown in Figure 1A, wherein anti-HLA-G represents anti-human leukocyte antigen-G (HLA-G) nanobody, whose amino acid sequence is SEQ ID NO: 1, and the nucleotide sequence encoding the amino acid sequence of the anti-HLA-G nanobody is SEQ ID NO: 4; anti-PDL1 represents anti-programmed cell death ligand 1 (PD-L1) nanobody, whose amino acid sequence is SEQ ID NO: 2, and the nucleotide sequence encoding the amino acid sequence of the anti-PD-L1 nanobody is SEQ ID NO: 5; anti-CD3e represents anti-CD3ε nanobody, whose amino acid sequence is SEQ ID NO: 3, and the nucleotide sequence encoding the amino acid sequence of the anti-CD3ε nanobody is SEQ ID NO: 6; signal peptide, whose amino acid sequence is SEQ ID NO: 7, and the nucleotide sequence encoding the amino acid sequence of the signal peptide is SEQ ID NO: 8; VHH1 represents heavy chain variable domain 1 (VHH1), that is, anti-PD-L1 nanobody; flexible linker, that is, linker, whose amino acid sequence is SEQ ID NO: 9, the nucleotide sequence encoding the amino acid sequence of the flexible linker is SEQ ID NO: 10; VHH2 represents heavy chain variable domain 2 (VHH2), which is an anti-HLA-G nanobody; VHH3 represents heavy chain variable domain 3 (VHH3), which is an anti-CD3ε nanobody; hinge; CH2 and CH3 represent human IgG1 crystallizable fragment region (fragmentcrystallizable region, Fc region), which is human IgG1 Fc-domain (Human IgG1 Fc-domain), and its amino acid sequence is SEQ ID NO: 11, and the nucleotide sequence encoding the amino acid sequence of the human IgG1 Fc-domain is SEQ ID NO: 12.

[0048] The restriction enzyme digestion results for Nb-TriTE are shown in Figure 1B , wherein lane 1 represents plasmid, lane 2 represents plasmid digested with XbaI-BamHI, and lane M represents DNA molecular weight standard (DNA marker).

[0049] The results of gel electrophoresis analysis of purified Nb-TriTE are shown in Figure 1C .

[0050] Example 2. Results of surface plasmon resonance binding assay (SPR binding assay) of Nb-TriTE

[0051] In this embodiment, the operating procedure of the surface plasmon resonance binding assay (surface plasmonresonance binding assay, SPR binding assay) of Nb-TriTE is as follows. CM5 or NTA chip is subjected to SPR analysis by BIAcore T200 (Biacore-GE Healthcare, Piscataway, NJ). In brief, protein (PD-L1, HLA-G or CD3 recombinant protein) samples are diluted in a concentration range of 20 μg / mL in 10mM buffer solution (pH 4.0, 5.5 or 6.0) to obtain maximum surface retention for fixation on the chip, following the preparation process and selecting the ligand (25, 12.5, 6.25, 3.125, 1.5625 and 0.78125nM) conditions with higher surface concentrations on the chip. Then there is regeneration scouting and surface performance testing. After regeneration scouting and surface performance testing, the regeneration method is then selected to run the experiment. Then select Binding Analysis and Direct Binding to study protein binding. Select Kinetic Analysis and select Mass Transfer to perform kinetic analysis of binding experiments. Afterwards, perform data analysis and determine kinetic constants.

[0052] The surface plasmon resonance binding analysis results of Nb-TriTE are shown in FIG. 2A to FIG. 2C ,in Figure 2A SPR kinetic analysis showing the binding of Nb-TriTE to PD-L1, the ligand is PD-L1, the analytical concentrations are 100, 50, 25, 12.5, 6.25, 3.125, 1.5625, 0.78125 nM, the flow rate is 30 μL / min, the association time is 120 seconds, and the dissociation time is 900 seconds. Atezolizumab is an IgG1 isotype fully humanized anti-PD-L1 monoclonal antibody used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer, small cell lung cancer and hepatocellular carcinoma. Anti-PDL1 represents anti-PD-L1 nanobody; Figure 2BSPR kinetic analysis showing the binding of Nb-TriTE to HLA-G, the ligand was HLA-G, the analytical concentrations were 305, 152.5, 76.25, 38.125, and 19.0625 nM, the flow rate was 30 μL / min, the association time was 180 s, the dissociation time was 360 s, anti-HLA-G indicated anti-HLA-G nanobody, anti-CD3e indicated anti-CD3ε nanobody, and 87G indicated commercial anti-HLA-G monoclonal antibody; Figure 2C SPR kinetic analysis showing the binding of Nb-TriTE to CD3ε, ligand is CD3ε, analysis concentration is 28.125, 56.25, 112.5, 225, 450, 900, 1800, 3600 nM, flow rate is 15 μL / min, association time is 350 seconds, dissociation time is 900 seconds, anti-CD3e represents anti-CD3ε nanobody, Muromonab-CD3 is an immunosuppressant for reducing acute rejection in organ transplant recipients, and is a monoclonal antibody against CD3 receptor on the surface of T cells, response (Response), time (Time). FIG. 2A to FIG. 2C It can be seen that Nb-TriTE has K values ​​within 2.6, 53.3 and 3.47 nM, respectively. D Effectively binds to PD-L1, HLA-G and CD3ε proteins.

[0053] Example 3. Results of T cell proliferation analysis using Nb-TriTE

[0054] In this example, the operation flow of the T cell (i.e., peripheral blood mononuclear cell) proliferation analysis using Nb-TriTE is as follows. 5 PBMC cells were seeded in 12-well plates, and clinical CD3ε monoclonal antibody OKT3 (5μg, Invitrogen, Cat: MA1-10175) and Proleukin (IL-2: 200U) or 10μg / ml Nb-TriTE were added. After 5 or 7 days, the total cell number was recorded, and then stained with FITC-conjugated CD3 monoclonal antibody (OKT3, 11-0037-42, eBioscience), and then analyzed by flow cytometry. The number of CD3 positive cells was calculated as the percentage of CD3 cells (%) × the total number of cells. The positive control group was Proleukin (IL-2: 200U) and OKT3 (5μg).

[0055] The results of T cell proliferation analysis by Nb-TriTE were shown in Figure 3, where PBMC stands for peripheral blood mononuclear cell. Figure 3 It can be seen that Nb-TriTE can promote T cell clustering, proliferation and activation.

[0056] Example 4. Immunocytochemistry (ICC) staining results of Nb-TriTE

[0057] In this example, for tumor cells, T cells and Nb-TriTE (i.e., V H The operation procedure of immunocytochemistry (ICC) analysis of H nanobody is as follows. Tumor cells (4x10 4 or 1x10 5 ) were seeded on coverslips in 6-well plates and incubated overnight. After the indicated treatments, cells were incubated with CellTracker Green, followed by the addition of Nb-TriTE and PBMC for one hour. Next, cells were fixed in 1% paraformaldehyde, washed with PBS, permeabilized with 0.1% Triton X-100 in PBS containing 0.5% BSA for 30 minutes, blocked with 2% BSA, and treated with specific antibodies in 2% BSA / PBS containing 0.05% Tween-20 (PBST). After washing, cells were treated with fluorescein-conjugated antibodies, washed with PBST, and mounted with aqueous mounting medium containing antifade and 4',6-diamidino-2-phenylindole (DAPI). Images were analyzed under a Leica TCS SP8X confocal microscope (Leica).

[0058] For tumor cells, T cells and Nb-TriTE (i.e. V H The immunocytochemical staining results of H nanobody) are shown in Figure 4 The cell line A549 used is a human non-small cell lung cancer cell line, PBMC stands for peripheral blood mononuclear cells, VHH stands for Nb-TriTE, and the number of cells in the above figure is 1x10 5 The number of cells in the figure below is 4x10 4 The results of this example show that Nb-TriTE has the ability to bind to A549 cells.

[0059] Example 5. Evaluation of the efficacy of Nb-TriTE and PBMC in enhancing cytolysis of human cancer cell lines

[0060] In this example, the effect of Nb-TriTE and PBMC on enhancing cell lysis of A549-human lung adenocarcinoma cell line, MDA-MB-231-human breast cancer cell line, U87-glioblastoma cell line, SKOV3-human ovarian cancer cell line and FaDu-human oral cancer cell line (purchased from American Type Culture Collection (ATCC)) was evaluated. The operation process is as follows. 1×10 5 Tumor cells were seeded on 12-well plates overnight. 5 Primary PBMCs were added to wells containing tumor cells. Nb-TriTE was added. After 48 hours, specific lysis of tumor cells by primary PBMCs was determined by LIVE / DEAD cell-mediated cytotoxicity assay using flow cytometry analysis.

[0061] The results of Nb-TriTE and PBMC in enhancing cytolysis of human cancer cell lines are shown in Figure 5A and Figure 5B ,in Figure 5A A549 represents human lung adenocarcinoma cell line, 231 represents MDA-MB-231-human breast cancer cell line, U87 represents glioblastoma cell line, SKOV3 represents human ovarian cancer cell line, FaDu represents human oral cancer cell line, the ratio of PBMC to A549 cells is 3:1, the concentration of Nb-TriTE is 10 μg / ml, and the co-culture lasts for 48 hours; Figure 5B The concentration of Nb-TriTE is 0, 1, 10, 100, 1000, 10000 and 100000 μg / ml, the effector (E) cells are PBMCs, the target (T) cells are A549 cells, and the E:T ratio represents the effector / target ratio. The results of this example demonstrate that Nb-TriTE enhances PBMC-induced cytotoxicity against tumor cells.

[0062] Example 6. Evaluation of the effect of Nb-TriTE on cytokine secretion in co-culture system by enzyme linked immunosorbent assay (ELISA)

[0063] In this example, human cytokines perforin, granzyme B, tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ) were measured using commercial ELISA kits (Thermo Fisher Scientific). The operation process is as follows. First, samples from Nb-TriTE, A549 cells, and PBMCs were collected and loaded on 96-well plates at 4°C overnight. The next day, the samples were removed and blocked with 3% skim milk for 2 hours at room temperature. Then, they were washed 5 times with PBST (0.05% Tween dissolved in PBS). After washing 5 times, biotinylated antibodies were added at room temperature for 2 hours. After washing 5 times, each well was treated with 100 μl of PBST containing streptavidin-horseradish peroxidase conjugates at room temperature for 2 hours. After washing with PBST for 7 times, 50 μl of TMB substrate (for detecting HRP activity) (ThermoFisher, Cat No: N301) was added, followed by adding 50 μl of stop solution (ThermoFisher, Cat No: N600) to terminate the reaction, and then measuring using an ELISA reader at a wavelength of 450 nm.

[0064] The results of this example are shown in Figure 6 , wherein A549 represents a human lung adenocarcinoma cell line, Nb represents a nanobody, the effector (E) cell is PBMC, the target (T) cell is A549 cell, the E:T ratio represents the effector / target ratio, # represents not detected, perforin, granzyme B, TNF-α represents tumor necrosis factor alpha, IFN-γ represents interferon gamma, and the co-culture lasts for 48 hours. The results of this example show that Nb-TriTE enhances the cytokine secretion of A549 co-cultured with PBMC.

[0065] Example 7. Evaluation of the efficacy of Nb-TriTE in blocking lung cancer growth in humanized mice

[0066] The operation process of this example is as follows. 6 to 8 week old NOD / SCIDγ (NSG) mice were purchased from The Jackson Laboratory. The mice were used for xenograft lung tumor model. For lung tumors, Luc +A549 cells were resuspended in PBS containing Matrigel, and then the cells (5x10 5 pcs / 20μL) were injected subcutaneously into the right back of the mouse. Seven days after implantation, thawed PDL1xHLA-GxCD3Nano-TriTE and PBMC (5x10 6 The mice were then injected with PDL1xHLA-GxCD3Nano-TriTE weekly. Tumor growth was monitored weekly via bioluminescence imaging using an invivo imaging system (IVIS) (PerkinElmer). On the designated days, the mice were sacrificed, and the tumors were harvested, measured, and photographed.

[0067] The results of this example are shown in 7A to 7C ,in Fig. 7A Luc represents luciferase, PBMC represents peripheral blood mononuclear cells, A549 represents human lung adenocarcinoma cell line, and TriTE represents Nb-TriTE. The results of this example show that Nb-TriTE can block the growth of lung cancer in humanized mice.

[0068] In summary, the immunomodulatory and anti-tumor related nano-antibodies of the present invention have been proved to specifically bind to HLA-G, PD-L1 and CD3ε through surface plasmon resonance binding analysis, to promote T cell cluster proliferation and activation through T cell (i.e. peripheral blood mononuclear cell) proliferation and activation analysis, to enhance CD3 positive T cell proliferation in PBMC, to bind to and kill tumor cells through immunocytochemistry (ICC) staining, to enhance cytokine secretion in tumor cells through enzyme-linked immunosorbent assay (ELISA), and to inhibit cancer cell growth through animal experiments, thereby achieving the effect of treating cancer and immune-related diseases. In particular, compared with the conventional antibodies that must be transfected into cells through vectors to express antibody functions and have the disadvantages of low yield and unclear effect, the immunomodulatory and anti-tumor related nano-antibodies of the present invention can be directly administered to individuals in need for treatment after large-scale preparation in vitro.

[0069] The above description is for illustrative purposes only and is not intended to be limiting. Any equivalent modifications or changes made thereto without departing from the spirit and scope of the present invention should be included in the appended claims. Sequence Listing <110> China Medical University Hospital, Taiwan; Shengan Biomedical Co., Ltd. <120> Immunomodulatory and anti-tumor related nanoantibodies, nucleic acid coding sequences thereof and applications <160> 12 <170> PatentIn version 3.5 <210> 1 <211> 128 <212> PRT <213> Artificial sequence <220> <223> Anti-HLA-G nanobody <400> 1 His Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Val Thr Ser Ala Tyr Thr Phe Ser Ala Ser 20 25 30 Gly Asn Cys Met Gly Trp Leu Arg Gln Ala Pro Gly Lys Gly Arg Glu 35 40 45 Gly Ile Ala Ala Thr Tyr Thr Arg Ser Ala Lys Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Gln Asp Asn Ala Lys Asn Thr 65 70 75 80 Val Tyr Leu Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Thr Tyr 85 90 95 Tyr Cys Ala Val Ala Arg Cys Ala Gly Arg Pro Asp Arg Ser Thr Leu 100 105 110 Thr Ser Phe Ala Trp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125 <210> 2 <211> 121 <212> PRT <213> Artificial sequence <220> <223> Anti-PD-L1 nanobody <400> 2 His Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Ile Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Arg 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Asn Ser Asp Gly Ser Asn Thr Tyr Tyr Ser Asp Ser Val 50 55 60 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Ile Asn Thr Leu Tyr 65 70 75 80 Leu Gln Leu Asn Ser Leu Lys Thr Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ser Arg Cys Pro Asp Ile Tyr Cys Gly Gly Gln Tyr Thr Tyr Arg Gly 100 105 110 Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 <210> 3 <211> 128 <212> PRT <213> Artificial sequence <220> <223> Anti-CD3 ε nanobody <400> 3 His Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Val Ser Gly Val Ile Phe Lys Asn Glu 20 25 30 Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ala Ala Ala Ser Pro Gly Gly Thr Ile Thr Tyr Tyr Gly Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Arg Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Leu Asp Pro Ser Thr Thr Ser Trp Ser Ile Ile Arg His Gly Pro 100 105 110 Ser Leu Trp Arg Tyr Ser Gly Arg Gly Thr Gln Val Thr Val Ser Ser 115 120 125 <210> 4 <211> 384 <212> DNA <213> Artificial sequence (Artificial sequence) <220> <223> Non-HLA-G activation <400> 4 60. cacgttcagt tggtagtc cggcggagga tcagtccagg ccgggggatc cctcaaactg tcttgtgtga ccagtgcata cactttctca gcttctgga actgcatggg atggttgagg caggctcccg gtaaaggcag ggaggggatc gccgccacct atacccgcag cgcaaagaca 180 tactatgccg actccgtgaa aggtaggttc accatctccc aggacaacgc caaaaacact gtttatcttc agatgaacgg tcttaagccc gaggacacag ccacctacta ttgtgccgtg 300. gcacgatgcg ctggcaggcc agaccgcagt accctgacca gcttcgcttg gtggggccaa 360 ggcacacagg tcaccgtcag ctcc 384 <210> 5 <211> 363 <212> DNA <213> Artificial sequence (Artificial sequence) <220> <223> Non-PD-L1 activation <400> 5 60. catgtgcaac tggtagaatc aggaggggc ctggtccagc caggcggttc cctcaggatc agttgtgccg catccgggtt tactttcagc tccagggcca tgtcctgggt gcgccaggct 120 cctggcaaag gtctggaatg ggtctccaca attaatagcg atggcagcaa tacctactat agcgactcag tgaaggatag attcactatc tcacgggata acgccattaa cactctgtac ctgcagctca acagcctgaa gaccgaagac acagccatgt actactgttc acggtgccca 360. gacatctact gcggcgggca gtacacctac cgcggacagg gcacacaggt gacagtgtct tcc 363 <210> 6 <211> 384 <212> DNA <213> Artificial sequence (Artificial sequence) <220> <223> Anti-CD3 inhibitor <400> 6 catgtgcagc tggtggagtc tgggggaggc tcggtgcagg ctggggggtc tctgagactc 120. tcctgtacag tgtctggagt catctttaag aacgagtaca tgggctggtt ccgccaggcc ccagggaagg agcgcgaggg ggtcgcagca gcttcgcctg gtggaacgat tacatactat 180 ggggactccg tgaagggccg attcaccatc tcccgagaca atgccaagaa cacggtgtat 240 ctgcaaatga accgcctgaa acctgaggac actgccatgt actactgtgc gttggatccc tcgactacgt catggtctat catccgccac ggtccatcgc tttggcgtta tagcggccgg 360 gggacccagg tcaccgtctc ctca 384 <210> 7 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Signal peptide <400> 7 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser <210> 8 <211> 57 <212> DNA <213> Artificial sequence <220> <223> Signal peptide <400> 8 atgggatgga gctgtattat tctcttcctt gtcgctacag caactggggt tcacagc 57 <210> 9 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Flexible joints <400> 9 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 15 <210> 10 <211> 45 <212> DNA <213> Artificial sequence <220> <223> Flexible joint <400> 10 ggaggaggag gctccggagg aggcggaagc ggaggaggag gaagc 45 <210> 11 <211> 232 <212> PRT <213> Artificial sequence <220> <223> Human IgG1 Fc - domain <400> 11 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Tyr 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 12 <211> 699 <212> DNA <213> Artificial sequence <220> <223> Human IgG1 Fc-region <400> 12 gaaccaaaga gttgcgacaa gactcatacc tgcccacat gtccagctcc tgaactgctg 60 gggggaccca gtgtgttcct gttccccct aagcccaagg atacccttat gattagcaga 120 acgcctgagg ttacttgtgt ggttgtcgat gtgagccatg aagatccaga ggtgaagttc 180 aactggtatt acgacggggt ggaggtgcat aacgctaaga ccaaccaag ggaggaacha 240 tataacagca cctatagagt cgtgtccgtc ctgaccgtgc tgcaccaaga ctggctcaat 300 ggtaagaat acagtgcaa ggttccac aaggcactgc ctgctccgat tgaaaaaacc 360 attagtaaag caaggggca acctcgagaa ccacaggtgt ataccctccc acctagtcgc 420 gaggagatga caagaacca ggtatccctc acctgtcttg tgaaggggtt ctacccaagt 480 gatacgccg ttgaatggga gtctaacggt cagccagaaa acactaca gaccactccg 540 cctgtcctgg actcagacgg gagctcttc ctgtacagca agttgaccgt ggataagagt 600 agatggcagc agggaatgt gttcagctgc agcgttgc acgaggccct gcacaatcac 660 tacacccaga atccctcag cctgtcacca gggaagtaa 699

Claims

1. An immunomodulatory and anti-tumor related nanobody, which specifically binds to human leukocyte antigen-G (HLA-G), programmed cell death ligand 1 (PD-L1) and CD3ε, and the immunomodulatory and anti-tumor related nanobody consists of a signal peptide, VHH1, a linker, VHH2, a linker, VHH3, a hinge, CH2 and CH3 arranged in sequence from N-terminus to C-terminus, wherein: The amino acid sequence of the VHH1 is shown in SEQ ID NO: 1, the amino acid sequence of the VHH2 is shown in SEQ ID NO: 2, and the amino acid sequence of the VHH3 is shown in SEQ ID NO:

3.

2. The immunomodulatory and anti-tumor related nanoantibody according to claim 1, wherein: The amino acid sequence is the amino acid sequence of the heavy chain variable domain of the immunomodulatory and anti-tumor related nanobody.

3. The immunomodulatory and anti-tumor-related nanobody as described in claim 2, further comprising a crystallizable fragment region.

4. The immunomodulatory and anti-tumor related nanoantibody according to claim 3, wherein: The crystallizable fragment region is the Fc region.

5. An isolated nucleic acid encoding the amino acid sequence of the immunomodulatory and anti-tumor related nanobody as described in any one of claims 1 to 4.

6. A pharmaceutical composition comprising the immunomodulatory and anti-tumor related nanobody according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

7. Use of the immunomodulatory and anti-tumor related nanoantibodies according to any one of claims 1 to 4 in the preparation of drugs for treating cancer and immune-related diseases, wherein: The cancer and immune-related disease are selected from the group consisting of lung adenocarcinoma, breast cancer, glioblastoma, ovarian cancer, oral cancer, and combinations thereof.